期刊文献+

Evaluation of the gastrointestinal anti-motility effect of Anacardium occidentale stem bark extract:A mechanistic study of antidiarrheal activity

下载PDF
导出
摘要 Diarrhea is a prevalent gastrointestinal problem associated with fatal implications.It is a huge public health concern that requires better alternatives to current drugs.This study investigated the mechanisms involved in the antidiarrheal activity of Anacardium occidentale(Ao) stem bark extract,a plant commonly used in the management of diarrhea in Nigeria.Methanolic stem bark extract of the plant was partitioned into three fractions:hexane fraction,ethyl acetate fraction(Ao EF) and methanol fraction.In vitro studies on the effect of these fractions on guinea pig ileum(GPI) strips,as well as the modulatory effect of Ao EF on standard agonists-and antagonists-induced GPI contraction and relaxation,revealed Ao EF as the most active fraction.In vivo studies to assess the effect of Ao EF on the dopaminergic,muscarinic,and serotonergic pathways were carried out using gastric emptying(GE) and gastrointestinal transit(GT) as experimental end points.Ao EF was subjected to GC-MS analysis,while the identified compounds were docked with the muscarinic acetylcholine receptor M3(CHRM3) using Autodock Vina.Results indicated that Ao EF inhibited GE and GT via inhibition of CHRM3.In addition,GC-MS analysis revealed the presence of 24 compounds in Ao EF,while docking indicated that octadecanoic acid 2-(2-hydroxylethoxy)ethyl ester exhibited the highest binding affinity to CHRM3.This study indicated that the antidiarrheal activity of Ao is through its antimotility effect via the inhibition of the muscarinic pathway.And since none of the identified compounds exhibited higher binding affinity to CHRM3 relative to loperamide,the antimotility activity of these phytoconstituents may be via synergism.
出处 《Journal of Pharmaceutical Analysis》 SCIE CAS CSCD 2021年第6期776-782,共7页 药物分析学报(英文版)
  • 相关文献

参考文献1

二级参考文献35

  • 1[1]Barnett M. Alternative opioids to morphine in palliative care: a review of current practice and evidence. Postgrad Med J 2001; 77:371-378
  • 2[2]Moulin DE, Iezzi A, Amireh R, Sharpe WK, Boyd D, Merskey H.Randomised trial of oral morphine for chronic non-cancer pain.Lancet 1996; 347:143-147
  • 3[3]McQuay H. Opioids in pain management. Lancet 1999; 353: 2229-2232
  • 4[4]Murphy DB, Sutton JA, Prescott LF, Murphy MB. Opioid-induced delay in gastric emptying: a peripheral mechanism in humans.Anesthesiology 1997; 87:765-770
  • 5[5]McCallum RW. Review of the current status of prokinetic agents in gastroenterology. Am J Gastroenterol 1985; 80:1008-1016
  • 6[6]De Luca A, Coupar IM. Insights into opioid action in the intestinal tract. Pharmacol Ther 1996; 69:103-115
  • 7[7]Meissner W, Schmidt U, Hartmann M, Kath R, Reinhart K. Oral naloxone reverses opioid-associated constipation. Pain 2000; 84:105-109
  • 8[8]Cheskin LJ, Chami TN, Johnson RE, Jaffe JH. Assessment of nalmefene glucuronide as a selective gut opioid antagonist. Drug Alcohol Depend 1995; 39:151-154
  • 9[9]Culpepper-Morgan JA, Inturrisi CE, Portenoy RK, Foley K,Houde RW, Marsh F, Kreek MJ. Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther 1992; 52:90-95
  • 10[10]Yuan CS, Foss JF, O′Connor M, Toledano A, Roizen MF, Moss J.Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther 1996; 59:469-475

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部